Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural M…

Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery.

Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery.

Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery. Journal of Thoracic Oncology 2018 October 23 [Link]. Harris EJ, Kao S, McCaughan B, Nakano T, Kondo N, Hyland R, Nowak AK, de Klerk NH, Brims …

Source: https://plus.google.com/106879421540319756254/posts/YnhyFP6d3HA

Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and S…

Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy.

Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy.

Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy. Photochemistry and Photobiology 2018 October 25 [Link]. Davis RW 4th, Snyder E, Miller J, Carter S, Houser C, Klampatsa A, Albelda S, Cengel K, …

Source: https://plus.google.com/106879421540319756254/posts/STXFwx8mbbM

Cell Medica to Manufacture WT1-TCR Therapy for Mesothelioma, Other Solid Tumors in 2018

Cell Medica to Manufacture WT1-TCR Therapy for Mesothelioma, Other Solid Tumors in 2018

Cell Medica to Manufacture WT1-TCR Therapy for Mesothelioma, Other Solid Tumors in 2018 | The Asbestos Cancer Organization

Cell Medica will begin manufacturing WT1-TCR cell therapy for solid tumors that have been difficult to treat with conventional therapies, such as mesothelioma and ovarian cancer. Cell Medica is planning to initiate a Phase 1/2 trial using a Dominant WT1-TCR version of the product in late 2018. WT1-TCR cell therapy involves taking a patient’s own immune cells…

Source: https://plus.google.com/106879421540319756254/posts/SRfUvgnanZz

Assessing Chemo and Immunotherapy Biomarkers at the Right Time Seen as Crucial in Mesotheliomia Mo…

Assessing Chemo and Immunotherapy Biomarkers at the Right Time Seen as Crucial in Mesotheliomia Monitoring

Assessing Chemo and Immunotherapy Biomarkers at the Right Time Seen as Crucial in Mesotheliomia Monitoring | The Asbestos Cancer Organization

The point at which doctors assess biomarkers of mesothelioma patients’ response to a combination of chemotherapy and immunotherapy is crucial to obtaining a clear picture of how the patients are doing, a study reports. The same applies to other cancers, according to the study, which was published in BMC Cancer. A biomarker is a biological indicator of the…

Source: https://plus.google.com/106879421540319756254/posts/YPyNXvJHKgY